INSM - Insmed Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
25.09
-0.32 (-1.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close25.41
Open25.28
Bid0.00 x 900
Ask0.00 x 800
Day's Range24.40 - 25.28
52 Week Range11.49 - 33.94
Volume394,357
Avg. Volume631,395
Market Cap1.922B
Beta2.16
PE Ratio (TTM)N/A
EPS (TTM)-3.19
Earnings DateAug 1, 2018 - Aug 6, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est38.44
Trade prices are not sourced from all markets
  • ACCESSWIRE7 days ago

    Free Technical Research on Insmed and Three More Biotech Equities

    On Thursday, July 12, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Wednesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Innoviva Inc. (NASDAQ: INVA), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Insmed Inc. (NASDAQ: INSM).

  • See what the IHS Markit Score report has to say about Insmed Inc.
    Markit17 days ago

    See what the IHS Markit Score report has to say about Insmed Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • GlobeNewswirelast month

    Insmed Announces FDA Advisory Committee Meeting to Review ALIS as a treatment for NTM Lung Disease Caused by MAC

    Insmed Incorporated (INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that the Division of Antimicrobial Products of the U.S. Food and Drug Administration (FDA) has notified the company of a planned advisory committee meeting to review data supporting Insmed’s New Drug Application (NDA) for ALIS (Amikacin Liposome Inhalation Suspension) for adult patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). “Currently there are no approved therapies for this rare, progressive and potentially fatal disease, representing a significant unmet need,” commented Will Lewis, President and Chief Executive Officer of Insmed. The Company has previously announced that the FDA accepted and considered the NDA for ALIS filed on May 27, 2018.

  • GlobeNewswirelast month

    Insmed to Present at Three June Conferences

    BRIDGEWATER, N.J., June 07, 2018-- Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that management will present at the ...

  • GlobeNewswire2 months ago

    Recent Analysis Shows Northwest Natural Gas, Brooks Automation, Insmed, Host Hotels & Resorts, Prospect Capital, and Inphi Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, May 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Northwest ...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and Insmed

    NEW YORK, NY / ACCESSWIRE / May 25, 2018 / U.S. markets were weighed down by the energy sector on Thursday as U.S. crude oil prices closed lower for the third consecutive session. However, major indexes ...

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 22) ArQule, Inc. (NASDAQ: ARQL ) AstraZeneca plc (ADR) (NYSE: ...

  • GlobeNewswire2 months ago

    Insmed Announces Presentations at the American Thoracic Society 2018 International Conference

    Insmed Incorporated (INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that detailed data from its ongoing Phase 3 CONVERT study of ALIS (amikacin liposome inhalation suspension) in adult patients with treatment refractory NTM lung disease caused by MAC were presented at the American Thoracic Society (ATS) 2018 International Conference. Results from 336 randomized patients in the Phase 3 CONVERT study cumulatively demonstrated that ALIS, combined with GBT, improved culture conversion rates.

  • ACCESSWIRE2 months ago

    Blog Exposure - FDA Accepted for Review Insmed’s Marketing Application for ALIS in NTM Lung Disease Caused by MAC

    LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on Insmed Inc. (NASDAQ: INSM), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=INSM as the Company's latest news hit the wire. On May 16, 2018, the Company announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALIS (Amikacin Liposome Inhalation Suspension) for treatment of adult patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC).

  • GlobeNewswire2 months ago

    Insmed Appoints Leo Lee to its Board of Directors

    Insmed Incorporated (INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the appointment of Leo Lee to its Board of Directors. “We are delighted to welcome Leo to the Insmed Board, where his deep global commercial expertise will be invaluable to Insmed as we prepare for the potential launch of ALIS (Amikacin Liposome Inhalation Suspension) in the United States,” said Will Lewis, President and Chief Executive Officer of Insmed. “I am honored to be joining the Insmed Board at such an exciting time for the company.

  • GlobeNewswire2 months ago

    Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC

    PDUFA Action Date Set for September 28, 2018. BRIDGEWATER, N.J., May 16, 2018-- Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced ...

  • See what the IHS Markit Score report has to say about Insmed Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Insmed Inc.

    This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 25. Index (PMI) data, output in the Healthcare sector is rising.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of INSM earnings conference call or presentation 2-May-18 12:30pm GMT

    Q1 2018 Insmed Inc Earnings Call

  • Insmed Incorporated (NASDAQ:INSM): Is Breakeven Near?
    Simply Wall St.2 months ago

    Insmed Incorporated (NASDAQ:INSM): Is Breakeven Near?

    Insmed Incorporated’s (NASDAQ:INSM): Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company’s loss has recently broadened since it announcedRead More...

  • ACCESSWIRE3 months ago

    Today's Research Reports on Trending Tickers: Insmed and Arena Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / May 3, 2018 / U.S. markets closed lower Wednesday after the Fed released a statement indicating an interest rate increase would be likely in the coming months. The Dow Jones ...

  • Associated Press3 months ago

    Insmed: 1Q Earnings Snapshot

    The Bridgewater, New Jersey-based company said it had a loss of 89 cents per share. Losses, adjusted to extinguish debt, came to 86 cents per share. The results fell short of Wall Street expectations. ...

  • GlobeNewswire3 months ago

    Insmed Reports First Quarter 2018 Financial Results and Provides Business Update

    Submitted NDA to FDA for Amikacin Liposome Inhalation Suspension in NTM lung disease caused by MAC; anticipates priority review Actively preparing for potential product launch of ALIS in 4 Q 2018. BRIDGEWATER, ...

  • GlobeNewswire3 months ago

    Insmed to Present at the Deutsche Bank 43rd Annual Health Care Conference

    BRIDGEWATER, N.J., May 01, 2018-- Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief ...

  • GlobeNewswire3 months ago

    Insmed to Host First Quarter 2018 Financial Results Conference Call on Wednesday, May 2, 2018

    Insmed Incorporated (INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it will release its first quarter 2018 financial results on Wednesday, May 2, 2018. Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Wednesday, May 2, 2018 to discuss the financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (844) 707-0669 (domestic) or (703) 639-1223 (international) and referencing conference ID number 4567628.

  • Benzinga3 months ago

    Insmed Shares To Outperform Through 2018 After 'Slow Start,' Credit Suisse Says In Upgrade

    A significant unmet need and high intent to treat from clinicians could serve as a meaningful offset against the uncertainty and commercial risk for Insmed's ALIS, Auster said. ALIS is the standard of case for refractory NTM MAC, Auster said, citing results of a survey of 26 clinicians.

  • See what the IHS Markit Score report has to say about Insmed Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Insmed Inc.

    Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Insmed (INSM): Moving Average Crossover Alert
    Zacks3 months ago

    Insmed (INSM): Moving Average Crossover Alert

    Insmed Incorporated (INSM) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Insmed

    NEW YORK, NY / ACCESSWIRE / April 3, 2018 / U.S. equities fell sharply on Monday, weighed down by losses in the technology sector and global trade concerns. The Dow Jones Industrial Average decreased 1.90 ...

  • ACCESSWIRE4 months ago

    Blog Exposure - Insmed Announced Submission of New Drug to FDA for Patients with Nontuberculous Mycobacterial Lung Disease

    Stock Monitor: ARCA biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 03, 2018 / Active-Investors.com has just released a free research report on Insmed Inc. (NASDAQ: INSM ). If you want ...